Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Tech Reporter.
Press releases published on May 1, 2025

HII Reports First Quarter 2025 Results
NEWPORT NEWS, Va., May 01, 2025 (GLOBE NEWSWIRE) -- HII (NYSE: HII) today reported results for the first quarter of fiscal 2025. Highlights First quarter revenues were $2.7 billion First quarter net earnings were $149 million or $3.79 diluted earnings per …

Draganfly and Autonome Labs Announce Teaming Agreement to Deliver UAV-Based Demining Mesh Deployment Solution
Tampa, FL, May 01, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) ("Draganfly" or the "Company") an industry-leading developer of drone solutions and systems is pleased to announce a strategic teaming agreement with Autonome …

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that …

Crane NXT Completes Acquisition of De La Rue Authentication Solutions
WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Crane NXT, Co. (NYSE: CXT) ("Crane NXT" or the "Company"), a premier industrial technology company, today announced it has completed its acquisition of De La Rue Authentication Solutions, a global leader in …

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter …

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and …

Eccogene Appoints Dr. Jai Patel as Chief Medical Officer
BOSTON and SHANGHAI, May 01, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced the appointment …

BioCryst Appoints Steve Frank to Board of Directors
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as …

Fortrea Named a Leader in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025
DURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a “Leader” for pharmacovigilance (PV) operations by Everest Group in its annual …

Climb Channel Solutions Launches Global Partnership with Accelsius LLC
EATONTOWN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), is excited to announce its new partnership with …

Lantronix to Report Fiscal 2025 Third Quarter Results on May 8, 2025
IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (the “Company”) (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling AI Edge Intelligence, today announced it will release financial results from its fiscal …

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a …

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress ( …

FactSet Increases Dividend
NORWALK, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, today announced that its Board of Directors approved a 6% increase in the regular quarterly cash …

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the …

Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference ( …

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity …

Enviri Corporation Reports First Quarter 2025 Results
First quarter revenues totaled $548 million GAAP consolidated loss from continuing operations of $11 million Q1 diluted loss per share from continuing operations of $0.15, including favorable impacts resulting from an amendment to a long-term …

Orezone Provides Update on RCF Block Trade to Australian Funds
VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to report that the recent block trade of 40 million common shares at a price of C$1.15 per share by …